Best of The Morning Dose: #145

This week's Morning Dose covers Retatrutide: The Phase 3 Results Are In, The Natty Plus Protocol, and How to Vet a Peptide Vendor.

In this week's issue 3 stories · 28-minute read

1PeptidesRetatrutide: The Phase 3 Results Are InLilly's triple agonist averaged 28.3% weight loss in its pivotal trial. Here's when it could reach pharmacies, and the new side effect to know about.Continues in this week's Morning Dose→2ProhormonesThe Natty Plus ProtocolThere's a middle ground between strictly natural and fully enhanced. Here's what it includes, and the trade-offs that come with it.Continues in this week's Morning Dose→3PeptidesHow to Vet a Peptide VendorThe best vendors publish a batch-specific COA you can verify with the lab yourself. This simple check weeds out most of the rest.Continues in this week's Morning Dose→

The Morning Dose

Read the full breakdown in this week's Morning Dose

Free. Every Monday. 5-minute read.

Welcome back to Muscle & Brawn!

This week, we’re looking at the Phase 3 results behind the biggest weight-loss numbers yet, the middle ground between natural and enhanced, and a five-minute check for vetting any peptide vendor.